CEACAM5 and rectal cancer: However, ypT3N0M0 rectal cancer patients with elevated pretreatment serum CEA levels who received ACT had superior 5-year CSS than those who did not receive ACT, while ypT3N0M0 rectal cancer patients with normal pretreatment serum CEA levels did not benefit from ACT.